Regulation of brain polyunsaturated fatty acid uptake and turnover

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 79, Issue 3-5, 2008, Pages 85-91

  Chen, Chuck T ^a   Green, Joshua T ^a   Orr, Sarah K ^a   Bazinet, Richard P ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Arachidonic acid; Brain; Docosahexaenoic acid; Phospholipase A2; Signalling; Transport

Indexed keywords

ARACHIDONIC ACID; ARACHIDONOYL COENZYME A; CARBAMAZEPINE; DOCOSAHEXAENOIC ACID; ERUCIC ACID; FLUOXETINE; ICOSAPENTAENOIC ACID; LAMOTRIGINE; LINOLEIC ACID; LINOLENIC ACID; LITHIUM; LONG CHAIN FATTY ACID COENZYME A LIGASE; N METHYL DEXTRO ASPARTIC ACID; PALMITIC ACID; PHOSPHOLIPASE A2; PHOSPHOLIPID; POLYUNSATURATED FATTY ACID; TOPIRAMATE; TRANSCRIPTION FACTOR AP 2; VALPROIC ACID;

ALZHEIMER DISEASE; ARTICLE; BIPOLAR DISORDER; BRAIN METABOLISM; CLINICAL TRIAL; DEPRESSION; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; ENZYME SYNTHESIS; EPILEPSY; EXPERIMENTAL RAT; FAT INTAKE; FATTY ACID METABOLISM; FATTY ACID TRANSPORT; HUMAN; IN VIVO STUDY; LIPID BRAIN LEVEL; LIPID COMPOSITION; MANIA; MOLECULAR DYNAMICS; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REGULATORY MECHANISM; TRANSPORT KINETICS; TURNOVER TIME;

ANIMALS; ANTIMANIC AGENTS; BRAIN; FATTY ACIDS, UNSATURATED; GROUP IV PHOSPHOLIPASES A2; HUMANS; MODELS, BIOLOGICAL; RATS;

RATTUS;

EID: 56449108741     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2008.09.003     Document Type: Article

References (89)

1. Svennerholm L. The distribution of lipids in the human nervous system. I. Analytical procedure. Lipids of foetal and newborn brain. J. Neurochem. 11 (1964) 839-853
2. Brenna J.T., and Diau G.Y. The influence of dietary docosahexaenoic acid and arachidonic acid on central nervous system polyunsaturated fatty acid composition. Prostaglandins Leukotrienes Essent. Fatty Acids 77 (2007) 247-250
3. M.A. Crawford, A.J. Sinclair, Nutritional influences in the evolution of mammalian brain, in: Lipids, Malnutrition and the Developing Brain, Ciba Foundation Symposium, 1971, pp. 267-292.
4. 2 and arachidonic acid release in signal transduction. Biochem. Soc. Trans. 18 (1990) 503-507
5. Kim H.Y. Novel metabolism of docosahexaenoic acid in neural cells. J. Biol. Chem. 282 (2007) 18661-18665
6. Orr S.K., and Bazinet R.P. The emerging role of docosahexaenoic acid in neuroinflammation. Curr. Opinion Invest. Drugs 9 (2008) 735-743
7. Bazan N.G. Lipid signaling in neural plasticity, brain repair, and neuroprotection. Mol. Neurobiol. 32 (2005) 89-103
8. Rao J.S., Ertley R.N., Lee H.J., et al. n-3 Polyunsaturated fatty acid deprivation in rats decreases frontal cortex BDNF via a p38 MAPK-dependent mechanism. Mol. Psychiatry 12 (2007) 36-46
9. Akbar M., Calderon F., Wen Z., and Kim H.Y. Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. Proc. Natl. Acad. Sci. USA 102 (2005) 10858-10863
10. Bosetti F. Arachidonic acid metabolism in brain physiology and pathology: lessons from genetically altered mouse models. J. Neurochem. 102 (2007) 577-586
11. Calon F., and Cole G. Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: evidence from animal studies. Prostaglandins Leukotrienes Essent. Fatty Acids 77 (2007) 287-293
12. Freeman M.P., Hibbeln J.R., Wisner K.L., et al. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J. Clin. Psychiatry 67 (2006) 1954-1967
13. Lands W.E.M., and Crawford C.G. Enzymes of Membrane Phospholipid Metabolism (1976), Plenum, New York pp. 3-85
14. Edmond J. Essential polyunsaturated fatty acids and the barrier to the brain: the components of a model for transport. J. Mol. Neurosci. 16 (2001) 181-193 discussion 215-121
15. Polozova A., Gionfriddo E., and Salem Jr. N. Effect of docosahexaenoic acid on tissue targeting and metabolism of plasma lipoproteins. Prostaglandins Leukotrienes Essent. Fatty Acids 75 (2006) 183-190
16. Thies F., Delachambre M.C., Bentejac M., Lagarde M., and Lecerf J. Unsaturated fatty acids esterified in 2-acyl-l-lysophosphatidylcholine bound to albumin are more efficiently taken up by the young rat brain than the unesterified form. J. Neurochem. 59 (1992) 1110-1116
17. Rapoport S.I., Chang M.C., and Spector A.A. Delivery and turnover of plasma-derived essential PUFAs in mammalian brain. J. Lipid Res. 42 (2001) 678-685
18. Robinson P.J., Noronha J., DeGeorge J.J., et al. A quantitative method for measuring regional in vivo fatty-acid incorporation into and turnover within brain phospholipids: review and critical analysis. Brain Res. 17 (1992) 187-214
19. Hamilton J.A., and Brunaldi K. A model for fatty acid transport into the brain. J. Mol. Neurosci. 33 (2007) 146-150
20. Bazinet R.P., Rao J.S., Chang L., Rapoport S.I., and Lee H.J. Chronic valproate does not alter the kinetics of docosahexaenoic acid within brain phospholipids of the unanesthetized rat. Psychopharmacol. Berlin 182 (2005) 180-185
21. Bazinet R.P., Rao J.S., Chang L., Rapoport S.I., and Lee H.J. Chronic carbamazepine decreases the incorporation rate and turnover of arachidonic acid but not docosahexaenoic acid in brain phospholipids of the unanesthetized rat: relevance to bipolar disorder. Biol. Psychiatry 59 (2006) 401-407
22. Chang M.C., Bell J.M., Purdon A.D., Chikhale E.G., and Grange E. Dynamics of docosahexaenoic acid metabolism in the central nervous system: lack of effect of chronic lithium treatment. Neurochem. Res. 24 (1999) 399-406
23. Chang M.C., Grange E., Rabin O., et al. Lithium decreases turnover of arachidonate in several brain phospholipids. Neurosci. Lett. 220 (1996) 171-174
24. Demar Jr. J.C., Lee H.J., Chang L., et al. Brain elongation of linoleic acid is a negligible source of the arachidonate in brain phospholipids of adult rats. Biochim. Biophys. Acta 1761 (2006) 1050-1059
25. Demar Jr. J.C., Ma K., Chang L., Bell J.M., and Rapoport S.I. Alpha-linolenic acid does not contribute appreciably to docosahexaenoic acid within brain phospholipids of adult rats fed a diet enriched in docosahexaenoic acid. J. Neurochem. 94 (2005) 1063-1076
26. Igarashi M., DeMar Jr. J.C., Ma K., et al. Docosahexaenoic acid synthesis from alpha-linolenic acid by rat brain is unaffected by dietary n-3 PUFA deprivation. J. Lipid Res. 48 (2007) 1150-1158
27. Lee H.J., Rao J.S., Chang L., Rapoport S.I., and Bazinet R.P. Chronic N-methyl-d-aspartate administration increases the turnover of arachidonic acid within brain phospholipids of the unanesthetized rat. J. Lipid Res. 49 (2008) 162-168
28. Golovko M.Y., and Murphy E.J. Uptake and metabolism of plasma-derived erucic acid by rat brain. J. Lipid Res. 47 (2006) 1289-1297
29. Contreras M.A., Greiner R.S., Chang M.C., et al. Nutritional deprivation of alpha-linolenic acid decreases but does not abolish turnover and availability of unacylated docosahexaenoic acid and docosahexaenoyl-CoA in rat brain. J. Neurochem. 75 (2000) 2392-2400
30. DeMar Jr. J.C., Ma K., Bell J.M., et al. One generation of n-3 polyunsaturated fatty acid deprivation increases depression and aggression test scores in rats. J. Lipid Res. 47 (2006) 172-180
31. DeMar Jr. J.C., Ma K., Bell J.M., and Rapoport S.I. Half-lives of docosahexaenoic acid in rat brain phospholipids are prolonged by 15 weeks of nutritional deprivation of n-3 polyunsaturated fatty acids. J. Neurochem. 91 (2004) 1125-1137
32. J.S. Rao, R.N. Ertley, S.I. Rapoport, R.P. Bazinet, H.J. Lee, Chronic NMDA administration to rats up-regulates frontal cortex cytosolic phospholipase A(2) and its transcription factor, activator protein-2, J. Neurochem. (2007).
33. Contreras M.A., Chang M.C., Rosenberger T.A., et al. Chronic nutritional deprivation of n-3 alpha-linolenic acid does not affect n-6 arachidonic acid recycling within brain phospholipids of awake rats. J. Neurochem. 79 (2001) 1090-1099
34. Esposito G., Giovacchini G., Der M., et al. Imaging signal transduction via arachidonic acid in the human brain during visual stimulation by means of positron emission tomography. NeuroImage 34 (2007) 1342-1351
35. G. Esposito, G. Giovacchini, J.S. Liow, et al., Imaging neuroinflammation in Alzheimer's disease with radiolabeled arachidonic acid and PET, J. Nucl. Med. (2008).
36. Chen C.T., Ma D.W., Kim J.H., Mount H.T., and Bazinet R.P. The low density lipoprotein receptor is not necessary for maintaining mouse brain polyunsaturated fatty acid concentrations. J. Lipid Res. 49 (2008) 147-152
37. Oldendorf W.H., Cornford M.E., and Brown W.J. The large apparent work capability of the blood-brain barrier: a study of the mitochondrial content of capillary endothelial cells in brain and other tissues of the rat. Ann. Neurol. 1 (1977) 409-417
38. Oldendorf W.H., Cornford M.E., and Brown W.J. The large apparent metabolic work capacity of the blood-brain barrier. Trans. Am. Neurol. Assoc. 101 (1976) 157-160
39. Mashek D.G., Bornfeldt K.E., Coleman R.A., et al. Revised nomenclature for the mammalian long-chain acyl-CoA synthetase gene family. J. Lipid Res. 45 (2004) 1958-1961
40. Milger K., Herrmann T., Becker C., et al. Cellular uptake of fatty acids driven by the ER-localized acyl-CoA synthetase FATP4. J. Cell Sci. 119 (2006) 4678-4688
41. DiRusso C.C., Li H., Darwis D., et al. Comparative biochemical studies of the murine fatty acid transport proteins (FATP) expressed in yeast. J. Biol. Chem. 280 (2005) 16829-16837
42. Jia Z., Moulson C.L., Pei Z., Miner J.H., and Watkins P.A. Fatty acid transport protein 4 is the principal very long chain fatty acyl-CoA synthetase in skin fibroblasts. J. Biol. Chem. 282 (2007) 20573-20583
43. MacDonald J.I., and Sprecher H. Phospholipid fatty acid remodeling in mammalian cells. Biochim. Biophys. Acta 1084 (1991) 105-121
44. Shimizu T., and Wolfe L.S. Arachidonic acid cascade and signal transduction. J. Neurochem. 55 (1990) 1-15
45. 2. Ann. Biochem. 269 (1999) 278-288
46. 2 in the central nervous system: implications for neurodegenerative diseases. J. Lipid Res. 45 (2004) 205-213
47. Alonso F., Henson P.M., and Leslie C.C. A cytosolic phospholipase in human neutrophils that hydrolyzes arachidonoyl-containing phosphatidylcholine. Biochim. Biophys. Acta 878 (1986) 273-280
48. Farooqui A.A., Horrocks L.A., and Farooqui T. Deacylation and reacylation of neural membrane glycerophospholipids. J. Mol. Neurosci. 14 (2000) 123-135
49. 2 in releasing docosahexaenoic acid from brain phospholipids. J. Lipid Res. 49 (2008) 939-944
50. 2 AdPLA. J. Biol. Chem. 283 (2008) 25428-25436
51. Cunnane S.C., Ryan M.A., Nadeau C.R., et al. Why is carbon from some polyunsaturates extensively recycled into lipid synthesis?. Lipids 38 (2003) 477-484
52. Lee H.J., Rao J.S., Rapoport S.I., and Bazinet R.P. Antimanic therapies target brain arachidonic acid signaling: lessons learned about the regulation of brain fatty acid metabolism. Prostaglandins Leukotrienes Essent. Fatty Acids 77 (2007) 239-246
53. Lee H.J., Ghelardoni S., Chang L., et al. Topiramate does not alter the kinetics of arachidonic or docosahexaenoic acid in brain phospholipids of the unanesthetized rat. Neurochem. Res. 30 (2005) 677-683
54. 2 activity and arachidonic acid turnover in brain phospholipids of the unanesthetized rat. Psychopharmacol. Berlin 190 (2006) 103-115
55. H.J. Lee, J.S. Rao, L. Chang, S.I. Rapoport, R.P. Bazinet, Chronic lamotrigine does not alter the turnover of arachidonic acid within brain phospholipids of the unanesthetized rat: implications for the treatment of bipolar disorder, Psychopharmacol. Berlin (2007).
56. DeGeorge J.J., Nariai T., Yamazaki S., Williams W.M., and Rapoport S.I. Arecoline-stimulated brain incorporation of intravenously administered fatty acids in unanesthetized rats. J. Neurochem. 56 (1991) 352-355
57. Serhan C.N., and Savill J. Resolution of infammation: the beginning programs the end. Nat. Immunol. 6 (2005) 1191-1197
58. Schwab J.M., Chiang N., Arita M., and Serhan C.N. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447 (2007) 869-874
59. Rao J.S., Lee H.J., Rapoport S.I., and Bazinet R.P. Mode of action of mood stabilizers: is the arachidonic acid cascade a common target?. Mol. Psychiatry 13 (2008) 585-596
60. Rapoport S.I., and Bosetti F. Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder?. Arch. Gen. Psychiatry 59 (2002) 592-596
61. 2. Prostaglandins Leukotrienes Essent. Fatty Acids 70 (2004) 373-376
62. 2 is a target for chronic lithium in rat brain. Neuroreport 10 (1999) 3887-3890
63. 2 or lipoxygenase/cytochrome P450 pathways. Brain Res. Bull. 63 (2004) 485-489
64. Bosetti F., Rintala J., Seemann R., et al. Chronic lithium downregulates cyclooxygenase-2 activity and prostaglandin E(2) concentration in rat brain. Mol. Psychiatry 7 (2002) 845-850
65. Rao J.S., Rapoport S.I., and Bosetti F. Decrease in the AP-2 DNA-binding activity and in the protein expression of AP-2 alpha and AP-2 beta in frontal cortex of rats treated with lithium for 6 Weeks. Neuropsychopharmacology 30 (2005) 2006-2013
66. Belmaker R.H. Bipolar disorder. N. Engl. J. Med. 351 (2004) 476-486
67. 2 expression and cyclooxygenase activity in rat brain. Biol. Psychiatry 56 (2004) 248-254
68. Rao J.S., Bazinet R.P., Rapoport S.I., and Lee H.J. Chronic administration of carbamazepine downregulates AP-2 DNA binding activity and AP-2α protein expression in rat frontal cortex. Biol. Psychiatry 61 (2007) 154-161
69. McElroy L., Keck Jr. P.E., Pope Jr. H.G., and Hudson J.I. Valproate in the treatment of bipolar disorder: literature review and clinical guidelines. J. Clin. Psychopharmacol. 12 (1992) 42S-52S
70. Chang M.C., Contreras M.A., Rosenberger T.A., et al. Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: a possible common effect of mood stabilizers. J. Neurochem. 77 (2001) 796-803
71. Rao J.S., Bazinet R.P., Rapoport S.I., and Lee H.J. Chronic treatment of rats with sodium valproate downregulates frontal cortex NF-kB DNA binding activity and COX-2 mRNA. Bipolar Disord. 9 (2007) 513-520
72. Bosetti F., Weerasinghe G.R., Rosenberger T.A., and Rapoport S.I. Valproic acid down-regulates the conversion of arachidonic acid to eicosanoids via cyclooxygenase-1 and -2 in rat brain. J. Neurochem. 85 (2003) 690-696
73. Laposata M., Reich E.L., and Majerus P.W. Arachidonoyl-CoA synthetase. Separation from nonspecific acyl-CoA synthetase and distribution in various cells and tissues. J. Biol. Chem. 260 (1985) 11016-11020
74. Bazinet R.P., Weis M.T., Rapoport S.I., and Rosenberger T.A. Valproic acid selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by brain microsomal long-chain fatty acyl-CoA synthetases: relevance to bipolar disorder. Psychopharmacology Berlin 184 (2006) 122-129
75. Wong D.T., Perry K.W., and Bymaster F.P. Case history: the discovery of fluoxetine hydrochloride (Prozac). Nat. Rev. 4 (2005) 764-774
76. Yatham L.N., Kennedy S.H., O'Donovan C., et al. Canadian network for mood and anxiety treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord. 7 Suppl. 3 (2005) 5-69
77. 2 in rat frontal cortex. Pharmacogenomics J. 6 (2006) 413-420
78. Dumuis A., Sebben M., Haynes L., Pin J.P., and Bockaert J. NMDA receptors activate the arachidonic acid cascade system in striatal neurons. Nature 336 (1988) 68-70
79. Sanacora G., Zarate C.A., Krystal J.H., and Manji H.K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat. Rev. 7 (2008) 426-437
80. Rao J.S., Ertley R.N., Rapoport S.I., Bazinet R.P., and Lee H.J. Chronic NMDA administration to rats up-regulates frontal cortex cytosolic phospholipase A(2) and its transcription factor, activator protein-2. J. Neurochem. 106 (2007) 1918-1927
81. Marcotte D. Use of topiramate, a new anti-epileptic as a mood stabilizer. J. Affect Disord. 50 (1998) 245-251
82. McElroy S.L., Arnold L.M., Shapira N.A., et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am. J. Psychiatry 160 (2003) 255-261
83. Vieta E., Sanchez-Moreno J., Goikolea J.M., et al. Adjunctive topiramate in bipolar II disorder. World J. Biol. Psychiatry 4 (2003) 172-176
84. Ghelardoni S., Bazinet R.P., Rapoport S.I., and Bosetti F. Topiramate does not alter expression in rat brain of enzymes of arachidonic acid metabolism. Psychopharmacology Berl 180 (2005) 523-529
85. York D.A., Singer L., Thomas S., and Bray G.A. Effect of topiramate on body weight and body composition of Osborne-Mendel rats fed a high-fat diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs. Nutrition 16 (2000) 967-975
86. Kushner S.F., Khan A., Lane R., and Olson W.H. Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord. 8 (2006) 15-27
87. Calabrese J.R., Rapport D.J., Youngstrom E.A., et al. New data on the use of lithium, divalproate, and lamotrigine in rapid cycling bipolar disorder. Eur. Psychiatry 20 (2005) 92-95
88. Lee H.J., Ertley R.N., Rapoport S.I., Bazinet R.P., and Rao J.S. Chronic administration of lamotrigine downregulates COX-2 mRNA and protein in rat frontal cortex. Neurochem. Res. 33 (2008) 861-866
89. Strokin M., Sergeeva M., and Reiser G. Prostaglandin synthesis in rat brain astrocytes is under the control of the n-3 docosahexaenoic acid, released by group VIB calcium-independent phospholipase A(2). J. Neurochem. 1 (2007) 1771-1782